On February 28, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, reported it will present pre-clinical data regarding its new anti-tumor product candidate during a poster presentation at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which will be held March 29 – April 3, 2019 at the Georgia World Congress Center in Atlanta, Georgia (Press release, OncoSec Medical, FEB 28, 2019, View Source [SID1234533816]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster is entitled, "Intratumoral administration of plasmid IL-12 and CXCL9 with membrane-bound anti-CD3 elicits robust anti-tumor immunity," and outlines pre-clinical data demonstrating that IL-12, in concert with CXCL9, inflames tumors. This leads to a brisk T cell infiltrate and anti-tumor activity, which when combined with anti-CD3 stimulation, drives a robust systemic T cell response. A link to the abstract of the presentation can be found here.
OncoSec’s clinical studies have demonstrated that plasmid IL-12 (tavokinogene telseplasmid) delivered intratumorally (TAVO) induces local expression of IL-12, converting immunologically cold tumors into inflamed immunogenic lesions, which is fundamental to generating objective responses in both treated and untreated distant tumors. In order to identify the key immunological components associated with an effective therapy, OncoSec’s research laboratory used immunological findings made from previously treated TAVO patients to design its new, second product candidate.
"This new product candidate builds upon our plasmid-based cancer immunotherapy platform by amplifying the power of intratumoral IL-12 through the addition of both CXCL9, a critical T cell chemokine, along with a membrane bound pan T cell stimulator, anti-CD3," noted Christopher Twitty, Ph.D., Chief Scientific Officer of OncoSec. "Importantly, this new product candidate integrates three key immunotherapeutic elements into a single novel, multi-gene expression platform that we believe has broad applicability across a number of tumor targets. We look forward to filing an Investigational New Drug application for this promising new product."
Presentation details are as follows:
Session Category:
Immunology
Session Title:
Combination Immunotherapies
Presenter:
Anandaroop Mukhopadhyay, PhD, Principal Scientist
Session Date and Time:
April 2, 2019 8:00 A.M – 12:00 P.M.
Poster Board Number:
5
Abstract Number
3195
Location:
Georgia World Congress Center, Exhibit Hall B, Poster Session 23
About